David John Lewis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2191698/publications.pdf

Version: 2024-02-01

11 papers	270 citations	1477746 6 h-index	1281420 11 g-index
13	13	13	404
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Adverse Events in the Digital Age: Finding the Sharpest Tool in the Box. Therapeutic Innovation and Regulatory Science, 2022, 56, 23-37.	0.8	1
2	Implementation of a Pregnancy Prevention Programme (PPP) with a Controlled Distribution System (CDS) for the Generic Teratogenic Phthalimides Thalidomide, Lenalidomide and Pomalidomide. Therapeutic Innovation and Regulatory Science, 2021, 55, 1155-1164.	0.8	7
3	Current Challenges in Labelling for Generic Medicinal Products: Company Core Data Sheet (CCDS) Development and Maintenance. Pharmaceutical Medicine, 2020, 34, 381-386.	1.0	2
4	Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities. Therapeutic Innovation and Regulatory Science, 2020, 54, 888-899.	0.8	27
5	Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR. Drug Safety, 2019, 42, 477-489.	1.4	37
6	Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, 2019, 42, 1393-1407.	1.4	60
7	Risk of Cleft Lip and/or Palate Associated With Antiepileptic Drugs: Postmarketing Safety Signal Detection and Evaluation of Information Presented to Prescribers and Patients. Therapeutic Innovation and Regulatory Science, 2019, 53, 110-119.	0.8	6
8	Social Media Surveillance of Multiple Sclerosis Medications Used During Pregnancy and Breastfeeding: Content Analysis. Journal of Medical Internet Research, 2019, 21, e13003.	2.1	18
9	The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe. Therapeutic Innovation and Regulatory Science, 2017, 51, 486-493.	0.8	6
10	Social media and pharmacovigilance: A review of the opportunities and challenges. British Journal of Clinical Pharmacology, 2015, 80, 910-920.	1.1	103
11	Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports. Pharmacoepidemiology and Drug Safety, 2015, 24, 971-979.	0.9	О